New FDA Guideline on Quality of Heparin
On the Road to 30,000 Members
Let us become the World's Leading GMP/GDP Compliance Community in 2026
In June 2013, the FDA published the final Guideline on "Crude Heparin" Quality. This guidance is intended to alert to the potential risk of crude (= unprocessed) heparin contamination.
The tests listed in the guideline intend to help avoiding the use of oversulfated chondroitin sulfate (OSCS). OSCS was the impurity identified in 2008 which appeared to have been intentionally mixed to heparin to reduce the cost of production. In the past, this OSCS mixture had caused the death of patients undergoing dialysis.
Furthermore, the identification and the control of animals' origin have to be ensured. Crude heparin is primarily sourced from porcine mucosa and not from bovine ones (ruminants) because of the higher risk of contamination with the BSE. The control of the animal origin is thus crucial.
In the guideline, the FDA recommends the use of a PCR method to confirm that crude heparin is of porcine sources. It is recommended to use a SAX HPLC method to exclude the presence of OSCS.
Click here to access the complete FDA Guideline.
Related GMP News
03.02.2026Your Input is Requested: AQCG Survey on OOS Investigations
03.02.2026Questions and Answers on System Suitability Tests (SST) - Part 2
03.02.2026Eurachem Publishes New Guide on the Fitness for Intended Use of Analytical Equipment and Systems
14.01.2026FDA Warning Letter: OOS Handling and HPLC Method Validation
07.01.2026Revised Ph. Eur. Chapters 2.9.42 and 2.9.43 on Dissolution Testing
07.01.2026Korean MFDS Publishes Data Collection on Dissolution Test Methods